Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer

Greg Durm, Nasser Hanna

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The landscape for the second- and third-line treatment of advanced non–small cell lung cancer has changed dramatically over the last two decades. Immunotherapeutic agents have become a preferred choice following progression on platinum-based first-line chemotherapy. However, there remains a role for cytotoxic chemotherapy and pemetrexed and docetaxel (with or without ramucirumab) are approved for single-agent use in the second-line setting. With the discovery of new genetic alterations and the development of novel targeted drugs, the treatment of advanced non–small cell lung cancer following progression on first-line therapy continues to become more complicated as new treatment algorithms evolve.

Original languageEnglish (US)
Pages (from-to)71-81
Number of pages11
JournalHematology/Oncology Clinics of North America
Volume31
Issue number1
DOIs
StatePublished - Feb 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
docetaxel
Pemetrexed
Therapeutics
Platinum
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Docetaxel
  • Erlotinib
  • Non–small cell lung cancer
  • Pemetrexed
  • Second-line treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer. / Durm, Greg; Hanna, Nasser.

In: Hematology/Oncology Clinics of North America, Vol. 31, No. 1, 01.02.2017, p. 71-81.

Research output: Contribution to journalReview article

@article{d48149aceae64a6e82eb54e93633118e,
title = "Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer",
abstract = "The landscape for the second- and third-line treatment of advanced non–small cell lung cancer has changed dramatically over the last two decades. Immunotherapeutic agents have become a preferred choice following progression on platinum-based first-line chemotherapy. However, there remains a role for cytotoxic chemotherapy and pemetrexed and docetaxel (with or without ramucirumab) are approved for single-agent use in the second-line setting. With the discovery of new genetic alterations and the development of novel targeted drugs, the treatment of advanced non–small cell lung cancer following progression on first-line therapy continues to become more complicated as new treatment algorithms evolve.",
keywords = "Chemotherapy, Docetaxel, Erlotinib, Non–small cell lung cancer, Pemetrexed, Second-line treatment",
author = "Greg Durm and Nasser Hanna",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.hoc.2016.08.002",
language = "English (US)",
volume = "31",
pages = "71--81",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer

AU - Durm, Greg

AU - Hanna, Nasser

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The landscape for the second- and third-line treatment of advanced non–small cell lung cancer has changed dramatically over the last two decades. Immunotherapeutic agents have become a preferred choice following progression on platinum-based first-line chemotherapy. However, there remains a role for cytotoxic chemotherapy and pemetrexed and docetaxel (with or without ramucirumab) are approved for single-agent use in the second-line setting. With the discovery of new genetic alterations and the development of novel targeted drugs, the treatment of advanced non–small cell lung cancer following progression on first-line therapy continues to become more complicated as new treatment algorithms evolve.

AB - The landscape for the second- and third-line treatment of advanced non–small cell lung cancer has changed dramatically over the last two decades. Immunotherapeutic agents have become a preferred choice following progression on platinum-based first-line chemotherapy. However, there remains a role for cytotoxic chemotherapy and pemetrexed and docetaxel (with or without ramucirumab) are approved for single-agent use in the second-line setting. With the discovery of new genetic alterations and the development of novel targeted drugs, the treatment of advanced non–small cell lung cancer following progression on first-line therapy continues to become more complicated as new treatment algorithms evolve.

KW - Chemotherapy

KW - Docetaxel

KW - Erlotinib

KW - Non–small cell lung cancer

KW - Pemetrexed

KW - Second-line treatment

UR - http://www.scopus.com/inward/record.url?scp=84998892621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998892621&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2016.08.002

DO - 10.1016/j.hoc.2016.08.002

M3 - Review article

C2 - 27912835

AN - SCOPUS:84998892621

VL - 31

SP - 71

EP - 81

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 1

ER -